JP2023543131A - シクロデキストリンによる心血管疾患の治療方法 - Google Patents

シクロデキストリンによる心血管疾患の治療方法 Download PDF

Info

Publication number
JP2023543131A
JP2023543131A JP2023513670A JP2023513670A JP2023543131A JP 2023543131 A JP2023543131 A JP 2023543131A JP 2023513670 A JP2023513670 A JP 2023513670A JP 2023513670 A JP2023513670 A JP 2023513670A JP 2023543131 A JP2023543131 A JP 2023543131A
Authority
JP
Japan
Prior art keywords
cyclodextrin
therapeutically effective
hydroxypropyl
administration
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543131A5 (cg-RX-API-DMAC10.html
Inventor
カーウィン，ダイアナ
カム，ジェイソン
Original Assignee
ベレン セラピューティクス ピー．ビー．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベレン セラピューティクス ピー．ビー．シー． filed Critical ベレン セラピューティクス ピー．ビー．シー．
Publication of JP2023543131A publication Critical patent/JP2023543131A/ja
Publication of JP2023543131A5 publication Critical patent/JP2023543131A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023513670A 2020-08-27 2021-08-27 シクロデキストリンによる心血管疾患の治療方法 Pending JP2023543131A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071257P 2020-08-27 2020-08-27
US63/071,257 2020-08-27
PCT/US2021/048084 WO2022047249A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cardiovascular disease with cyclodextrins

Publications (2)

Publication Number Publication Date
JP2023543131A true JP2023543131A (ja) 2023-10-13
JP2023543131A5 JP2023543131A5 (cg-RX-API-DMAC10.html) 2024-08-13

Family

ID=80353287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513670A Pending JP2023543131A (ja) 2020-08-27 2021-08-27 シクロデキストリンによる心血管疾患の治療方法

Country Status (14)

Country Link
US (2) US20240000826A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203974A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543131A (cg-RX-API-DMAC10.html)
KR (1) KR20230104119A (cg-RX-API-DMAC10.html)
CN (1) CN116322644A (cg-RX-API-DMAC10.html)
AU (1) AU2021331487A1 (cg-RX-API-DMAC10.html)
CA (1) CA3189915A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023003656A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230135A (cg-RX-API-DMAC10.html)
IL (1) IL300805A (cg-RX-API-DMAC10.html)
JO (1) JOP20230043A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002418A (cg-RX-API-DMAC10.html)
PE (1) PE20231169A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022047249A1 (cg-RX-API-DMAC10.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US20190262385A1 (en) * 2012-04-13 2019-08-29 L&F Research Llc Method of using cyclodextrin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US20190262385A1 (en) * 2012-04-13 2019-08-29 L&F Research Llc Method of using cyclodextrin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GREBE A. ET AL.: "Targeting choresterol crystals in atherosclerosis with choresterol solubilizing 2-hydroxypropyl-beta", BONNDOC [ONLINE], JPN6026026390, 21 December 2016 (2016-12-21), pages 1 - 132, ISSN: 0005897047 *
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 73, no. 5, JPN6025039285, 2019, pages 334 - 342, ISSN: 0005897048 *
MOLECULES, vol. 21, JPN6025039283, 2016, pages 1748, ISSN: 0005897044 *
REJUVENATION RESEARCH, vol. 19, no. 3, JPN6025039281, 2016, pages 252 - 255, ISSN: 0005897043 *
SCIENCE TRANSLATIONAL MEDICINE, vol. 8, JPN6025039284, 2016, pages 333 - 50, ISSN: 0005897045 *
THE FASEB JOURNAL, vol. 22, JPN6026026388, 2007, pages 659 - 661, ISSN: 0005897046 *

Also Published As

Publication number Publication date
EP4203974A1 (en) 2023-07-05
CA3189915A1 (en) 2022-03-03
IL300805A (en) 2023-04-01
CN116322644A (zh) 2023-06-23
KR20230104119A (ko) 2023-07-07
MX2023002418A (es) 2023-07-11
EP4203974A4 (en) 2024-08-07
JOP20230043A1 (ar) 2023-02-27
CR20230135A (es) 2023-07-19
CO2023003656A2 (es) 2023-08-09
AU2021331487A1 (en) 2023-03-16
WO2022047249A1 (en) 2022-03-03
US20240000826A1 (en) 2024-01-04
US20230091966A1 (en) 2023-03-23
PE20231169A1 (es) 2023-07-26

Similar Documents

Publication Publication Date Title
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
KR20130026504A (ko) 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
JP2025508660A (ja) ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
Kurosawa et al. A case of an increase in prothrombin Time-International normalized ratio by interaction between warfarin and Baloxavir Marboxil in a patient on implantable ventricular assist device
JP2023543132A (ja) シクロデキストリンによるコレステロール結晶塞栓症の予防方法
CN104507478A (zh) 用于治疗急性冠状动脉综合征的烟酰胺衍生物
JP5648287B2 (ja) 冠動脈の描出能改善剤
Lyseng-Williamson Ferric maltol in iron deficiency anaemia in patients with inflammatory bowel disease: a guide to its use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260731